BACKGROUND: Undifferentiated pleomorphic sarcomas (UPS) present a diagnostic and therapeutic challenge. Identification of prognostic molecular markers is required for the discovery of novel treatment approaches. The purpose of this study was to correlate clinicopathologic variables, expression of tyrosine kinase receptors, and markers of cell cycle progression and survival with oncologic outcomes. METHODS: A tissue microarray containing 208 primary UPS samples was analyzed by immunohistochemistry for protein markers and in situ hybridization for microRNA. Staining results were correlated with clinicopathologic features and oncologic outcomes. Univariate and multivariate analyses were conducted to assess associations between expression of protein markers, mi-RNA, and outcome. RESULTS: At a median follow-up of 3.9 years (9 years for survivors), 5-year disease-specific survival (DSS) was 63 %. Clinical variables associated with improved DSS included age <61 years, tumor size <10 cm, margin-negative resection, and sporadic-tumor status. At the protein level, loss of cyclin D1 (p = 0.06), pEGFR (p = 0.023), pIGF-1R (p = 0.022), and PTEN (p < 0.001) and overexpression of AXL (p = 0.015) were associated with reduced DSS on univariate analysis. Ki67, PCNA, and pEGFR were more highly expressed in sporadic UPS than radiation-associated (RA-UPS), whereas RA-UPS samples expressed higher levels of both phosphorylated and total IGF-1R. DISCUSSION: Loss of cyclin D1, overexpression of AXL, and loss of PTEN are associated with poor cancer-specific outcomes and warrant further investigation in UPS. The differences in protein expression in sporadic versus RA-UPS may indicate that the activated molecular signaling nodes may be different for each specific histology and also could explain the aggressive phenotype seen in RA-UPS compared with the sporadic lesions.
BACKGROUND:Undifferentiated pleomorphic sarcomas (UPS) present a diagnostic and therapeutic challenge. Identification of prognostic molecular markers is required for the discovery of novel treatment approaches. The purpose of this study was to correlate clinicopathologic variables, expression of tyrosine kinase receptors, and markers of cell cycle progression and survival with oncologic outcomes. METHODS: A tissue microarray containing 208 primary UPS samples was analyzed by immunohistochemistry for protein markers and in situ hybridization for microRNA. Staining results were correlated with clinicopathologic features and oncologic outcomes. Univariate and multivariate analyses were conducted to assess associations between expression of protein markers, mi-RNA, and outcome. RESULTS: At a median follow-up of 3.9 years (9 years for survivors), 5-year disease-specific survival (DSS) was 63 %. Clinical variables associated with improved DSS included age <61 years, tumor size <10 cm, margin-negative resection, and sporadic-tumor status. At the protein level, loss of cyclin D1 (p = 0.06), pEGFR (p = 0.023), pIGF-1R (p = 0.022), and PTEN (p < 0.001) and overexpression of AXL (p = 0.015) were associated with reduced DSS on univariate analysis. Ki67, PCNA, and pEGFR were more highly expressed in sporadic UPS than radiation-associated (RA-UPS), whereas RA-UPS samples expressed higher levels of both phosphorylated and total IGF-1R. DISCUSSION: Loss of cyclin D1, overexpression of AXL, and loss of PTEN are associated with poor cancer-specific outcomes and warrant further investigation in UPS. The differences in protein expression in sporadic versus RA-UPS may indicate that the activated molecular signaling nodes may be different for each specific histology and also could explain the aggressive phenotype seen in RA-UPS compared with the sporadic lesions.
Authors: Joal D Beane; James C Yang; Donald White; Seth M Steinberg; Steven A Rosenberg; Udo Rudloff Journal: Ann Surg Oncol Date: 2014-04-23 Impact factor: 5.344
Authors: Guy Lahat; Pingyu Zhang; Quan-Sheng Zhu; Keila Torres; Markus Ghadimi; Kerrington D Smith; Wei-Lien Wang; Alexander J Lazar; Dina Lev Journal: Histopathology Date: 2011-09 Impact factor: 5.087
Authors: Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch Journal: J Clin Invest Date: 2014-09-02 Impact factor: 14.808
Authors: Jianguo Huang; Mohit Sachdeva; Eric Xu; Timothy J Robinson; Lixia Luo; Yan Ma; Nerissa T Williams; Omar Lopez; Lisa D Cervia; Fan Yuan; Xiaodi Qin; Dadong Zhang; Kouros Owzar; Nalan Gokgoz; Andrew Seto; Tomoyo Okada; Samuel Singer; Irene L Andrulis; Jay S Wunder; Alexander J Lazar; Brian P Rubin; Krista Pipho; Stephano S Mello; Jimena Giudice; David G Kirsch Journal: Mol Cancer Res Date: 2020-06-19 Impact factor: 5.852
Authors: Angela D Bhalla; Sharon M Landers; Anand K Singh; Jace P Landry; Michelle G Yeagley; Gabryella S B Myerson; Cristian B Delgado-Baez; Stephanie Dunnand; Theresa Nguyen; Xiaoyan Ma; Svetlana Bolshakov; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Xizeng Mao; Xingzhi Song; Alexander J Lazar; Ian E McCutcheon; John M Slopis; Joseph A Ludwig; Dina C Lev; Kunal Rai; Keila E Torres Journal: Lab Invest Date: 2022-02-28 Impact factor: 5.662
Authors: Omar Al Laham; Gheed Abdul Khalek; Hazar Alboushi; Abd Al Hameed Al Mohammad; Mohamad Almaydaani; Alaa Alhanwt Journal: Int J Surg Case Rep Date: 2022-09-19
Authors: Anthony P Conley; Wei-Lien Wang; John A Livingston; Vinod Ravi; Jen-Wei Tsai; Ali Ali; Davis R Ingram; Caitlin D Lowery; Christina L Roland; Neeta Somaiah; Patrick Hwu; Cassian Yee; Vivek Subbiah; Andrew Futreal; Alexander J Lazar; Shreyaskumar Patel; Jason Roszik Journal: Cancers (Basel) Date: 2019-05-15 Impact factor: 6.639
Authors: Hope M Amm; Patricia DeVilliers; Ambika R Srivastava; Marina G Diniz; Gene P Siegal; Mary MacDougall Journal: Clin Exp Dent Res Date: 2020-07-11